Form 4: Galectin Therapeutics CMO Executes Stock Option Exercise
Statement of Changes in Beneficial Ownership
Chief Medical Officer Jamil Khurram exercised 568 stock options and sold the resulting shares under a Rule 10b5-1 plan.
Summary
- Chief Medical Officer Jamil Khurram exercised 568 stock options at a strike price of $1.23 per share.
- The resulting 568 shares of common stock were immediately sold at a weighted average price of $3.1004 per share.
- The transaction was executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 2, 2026.
- Following the transaction, the reporting person holds 0 shares of common stock directly, with 40,057 derivative securities remaining.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transaction was a routine, pre-planned exercise of equity compensation.
Positives
- The transaction was conducted under a pre-planned Rule 10b5-1 arrangement, indicating a systematic approach to equity management rather than reactive selling.
Negatives
- The reporting person reduced their direct common stock holdings to zero following the sale.
Risks
- Reliance on Rule 10b5-1 plans does not eliminate market risk or the potential for negative perception regarding insider selling.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider transactions executed under Rule 10b5-1 plans are standard corporate governance practices and generally do not signal changes in company fundamentals or management sentiment.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is a standard industry practice for executives to manage equity compensation while avoiding potential conflicts with insider trading regulations.
Stakeholder Impact
- Minimal impact on shareholders as the transaction volume is small and pre-planned.
Next Steps
- Future vesting of remaining 40,057 options scheduled for June 30, 2026, and December 31, 2026.
Key Dates
| Date | Description |
|---|---|
| 02/02/2026 | Date the Rule 10b5-1 trading plan was adopted. |
| 05/15/2026 | Date the Rule 10b5-1 plan was disclosed in the Form 10-Q. |
| 05/26/2026 | Date of the earliest transaction (option exercise and sale). |
| 05/28/2026 | Date the Form 4 was signed and filed. |
Keywords
GALT, Galectin Therapeutics, Insider Trading, Form 4, Stock Options, Chief Medical Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.